Evidence map›Paper›PMID 42823779›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Facial Foundation Model for Clinical Biomarker Prediction and Real-World Mobile Deployment.

Tingfeng Xu, Huixuan Xu, Li Lin, Fei Wang, Yaodong Ding, Shuangqiao Liao, Xingyu Chen, Jichen Wen, Hongqiang Zhao, Jing Hao and 6 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tingfeng Xu *China National Center for Bioinformation, Beijing, China.
Huixuan Xu *University of Chinese Academy of Sciences, Beijing, China.ORCID https://orcid.org/0009-0001-1224-3080
Li Lin *Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Fei Wang *China National Center for Bioinformation, Beijing, China.
Yaodong DingBeijing Anzhen Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-5388-2321
Shuangqiao LiaoChina National Center for Bioinformation, Beijing, China.
Xingyu ChenChina National Center for Bioinformation, Beijing, China.
Jichen WenChina National Center for Bioinformation, Beijing, China.
Hongqiang ZhaoChina National Center for Bioinformation, Beijing, China.
Jing HaoChina National Center for Bioinformation, Beijing, China.
Weixiang ZhaoChina National Center for Bioinformation, Beijing, China.
Gong ZhangCardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.
Shiguang ShanUniversity of Chinese Academy of Sciences, Beijing, China.
Yong ZengBeijing Anzhen Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0001-6983-0799
Hu HanUniversity of Chinese Academy of Sciences, Beijing, China.ORCID https://orcid.org/0000-0001-6010-1792
Minxian WangChina National Center for Bioinformation, Beijing, China.ORCID https://orcid.org/0000-0002-3753-508X

Funding

Beijing Municipal Science and Technology Commission Z211100003521022Capital Health Development Research Special Project 2024-1-2061National Natural Science Foundation of China 82470352Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0503201Noncommunicable Chronic Diseases-National Science and Technology Major Project 2025ZD0552006Pioneering Action Grants of the Chinese Academy of SciencesScientific data Plan of Chinese Academy of Sciences CAS-SJ2025-01Strategic Priority Research Program of the Chinese Academy of Sciences XDA0460400
6 · The paper itself

Abstract

While most biomarkers currently rely on invasive laboratory testing, which limits large-scale or repeated screening, scalable non-invasive methods could transform population screening and personalized health management. Facial photographs, as a ubiquitous and non-invasive data source, offer such potential but remain underexplored for clinical biomarker prediction. Existing supervised approaches are constrained by the availability of clinically labeled data, whereas general-purpose vision models are optimized for non-clinical tasks and may inadequately capture subtle, multiscale, and spatially distributed clinical facial features. To address these limitations, we developed MedicalFaceFound, a facial foundation model pretrained on over 10 million images and evaluated across 62 biomarkers spanning eight physiological systems. It performed best among the Swin-Large and ResNet18 for 45 (73%) biomarkers and generalized across four independent external cohorts (median Pearson's r = 0.172), with strong performance for RBC, eGFR, and HDL-C (median r = 0.478, 0.442, and 0.430, respectively). MedicalFaceFound also outperformed polygenic risk score models for 14 of 26 biomarkers, and face-estimated cardiovascular biomarkers were strongly associated with coronary stenosis (AUC = 0.66). The model retained predictive performance with 400 labeled samples and was feasible to deploy as a smartphone application, supporting scalable, non-invasive biomarker assessment and personalized risk screening.

Indexed as

coronary artery diseasedeep learningface analysisheart disease predictionmedical geneticspredictive biomarkerrisk prediction modelssoftware deployment

Identifiers

PMID42823779
PMCPMC13631392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.